Getting latest data loading
Home / Trade Alert / Buy – Smith & Nephew

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

Buy – Smith & Nephew - 29 October 2018

Trade Parameters

  • Opening Price: 1284p
  • Stop Loss: 1235p (49p/3.8% below)
  • Profit Limit: 1410p (126p/9.8% above)
  • Reward vs Risk: 2.6x
  • CFD Margin: 20% (5% for those with Professional Status accounts)

Technical Observations – For

  • Bullish rebound and reversal
  • Directional Indicator converging Bullishly
  • Stochastics broken up above MACD
  • Momentum rebounded towards neutral

Technical Observations – Against

  • No volume jump on rebound
  • MACD & Momentum still negative
  • No bullish cross by directional indicators
  • No Point & Figure chart reversal

Analyst Comments

Defensive/non-cyclical names should fare better in the case of a general market downturn. The shares rallied after H1 results at end-July after reiterating full year profits guidance. Strong growth in Emerging Markets (China, Middle East). Medical Technology can be a target for M&A.

Risks to Smith & Nephew include a poor trading update on Thursday, a sustained market recovery/rally that favours risk assets over defensive/non-cyclicals, product disappointments and broker downgrades.

Brokers/analysts are bullish on the shares with only 6% suggesting Sell. This is supported by 93% of broker price targets suggesting upside from current levels, to a consensus target of 1418p, which is right in-line with our short-term target of repeating October’s own revisit of 2018 highs.

Next Event: Q3 Trading Report, 1 Nov (Thurs)

Latest Broker 12-Month Consensus:  35% Buy, 59% Hold, 6% Sell (full breakdown on request)

Source: DowJones Newswires, Reuters News, Bloomberg  or Company Press releases

2-year (daily) - MACD, Stochastics, Trend Strength, RSI, Momentum

1wk 1m 3m 6m 1yr 2yr 3yr 4yr 5yr
Perf % 1.3 -7.7 -5.6 -6.8 -10.2 8.1 11.3 30.9 61.1
Back to Top

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Prepared by Michael van Dulken, Head of Research
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.